Zantac Ovarian Cancer

The Food and Drug Administration recently pulled Zantac and other ranitidine products from the market based on the discovery that they contain NDMA (N-Nitrosodimethylamine). NDMA is a contaminant that is widely deemed a probable carcinogen (cancer-causing agent).  One of the associated cancers is ovarian cancer.

Ovarian Cancer

The Mayo Clinic shares that ovarian cancer begins in the ovaries and often spreads to the pelvis and abdomen before it is detected, which renders the disease much more difficult to effectively treat. While cancer that is confined to the ovaries is more likely to be treated successfully, the disease rarely presents with symptoms at this stage – and the few related symptoms are often misinterpreted as representative of more common and benign health concerns. Those signs and symptoms that can be associated with the later stages of ovarian cancer may include:

• Feeling full soon after beginning to eat
• Bloating or swelling of the abdomen
• Unintentional weight loss
• the frequent need to urinate
• Constipation or other changes in one’s bowel habits
• Discomfort or pain in the pelvic region

If you experience any of these symptoms – or others that concern you – seek medical attention to help rule out a serious health concern.

Review Your Case with a Dedicated Drug Injury Lawyer

If you took Zantac regularly for heartburn or another ailment and were later diagnosed with ovarian cancer, you may have legal recourse that can help you recover on your losses and obtain the compensation to which you are entitled. Contact a formidable drug injury lawyer today.